In an exploratory analysis of the TALAPRO-2 results for DDR-mutated patients, the greatest benefit was observed for patients with mutations in BRCA2 (HR, 0.19 [95% CI, 0.10 to 0.38]), no clear rPFS ...
*During data validation and verification for the manuscript, one patient that was originally reported as having a response in the 2021 AACR Annual Meeting presentation of this cohort was found instead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback